[Immunologic effects of anti-B-lymphocyte antibodies].
Cartron
G
G
Service d'onco-hématologie, clinique Victor-Hugo, Le Mans, France. guillaume.cartron@med.univ-tours.fr
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D017209:Apoptosis / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D003167:Complement Activation / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007155:Immunologic Factors / Q000276:immunology* / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000276:immunology; D008262:Macrophage Activation / Q000276:immunology; D009503:Neutropenia / Q000276:immunology; D018375:Neutrophil Activation / Q000276:immunology; D011961:Receptors, Fc / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007136:Immunoglobulins; D007155:Immunologic Factors; D011961:Receptors, Fc; D000069283:Rituximab